Best of the Best Dry Eye Treatment Options:

Best Dry Eye Options

Healing tissue is the Holy Grail of treating Dry Eye Disease and Meibomian Gland Dysfunction. Second comes anti-inflammatory tools. Last is fixing the brain’s perception of pain—helpful, but ultimately a band‑aid that does not address the root cause.

REGENERATIVE / HEALING / REPAIR TIER
(Ranked from strongest clinical evidence → emerging/experimental)

• ☐ 1. Platelet‑Rich Plasma (PRP) Eye Drops^1,2
  High concentrations of epitheliotrophic growth factors and cytokines. Randomized trials and meta‑analyses show significant improvement in signs and symptoms of moderate–severe dry eye and ocular surface disease, often equal or superior to autologous serum tears.
• ☐ 2. Autologous Serum Tears (20–100%)^2,3
  Biologic tear substitute containing EGF, TGF‑β, vitamin A, and other serum factors. Multiple RCTs demonstrate improved corneal staining, tear stability, and symptoms in severe dry eye, Sjögren’s, and persistent epithelial defects.
• ☐ 3. Cord Blood Serum Eye Drops^3,4
  Derived from umbilical cord blood with higher levels of certain growth factors compared with adult serum. Clinical studies report enhanced epithelial healing and symptom relief in severe ocular surface disease and pediatric indications.
• ☐ 4. Amniotic Membrane (Prokera, Fresh, etc.)^5,6
  Biologic scaffold with anti‑inflammatory, anti‑fibrotic, and pro‑healing properties. Robust clinical literature supports its use in persistent epithelial defects, severe dry eye, and neurotrophic keratitis.
• ☐ 5. Amniotic Membrane–Derived Drops⁶
  Cryopreserved or processed amniotic fluid/membrane solutions delivering soluble growth factors without a physical graft. Early clinical data show improved epithelial healing and symptom relief.
• ☐ 6. Cenegermin (Oxervate – Recombinant Human Nerve Growth Factor)^7,8
  FDA‑approved for neurotrophic keratitis. Phase II/III trials show significant corneal epithelial healing and corneal nerve regeneration, with indirect reduction of chronic surface inflammation.
• ☐ 7. Limbal Stem Cell–Based Therapies (CLAU, CLET, SLET)⁹
  Surgical transplantation of limbal stem cells for limbal stem cell deficiency. Long‑term studies demonstrate ocular surface reconstruction, epithelial stability, and visual rehabilitation.
• ☐ 8. Mesenchymal Stem Cell–Based Therapies (Adipose‑ or Bone Marrow–Derived)^10,11
  MSCs secrete anti‑inflammatory and trophic factors. Preclinical and early clinical studies suggest immunomodulation and promotion of epithelial healing, but remain investigational for dry eye.
• ☐ 9. Exosome‑Based / Cell‑Free Regenerative Therapies^11,12
  MSC‑derived exosomes show promising epithelial and nerve‑regenerative effects in preclinical ocular surface models. Early human data are emerging but remain experimental.

ANTI‑INFLAMMATORY OPTIONS FOR DRY EYE DISEASE
NON‑STEROIDAL (Ranked strongest → milder)

• ☐ 1. PRP (Platelet‑Rich Plasma) Eye Drops¹
• ☐ 2. Autologous Serum Tears^1,2
• ☐ 3. Cord Blood Serum Eye Drops²
• ☐ 4. Amniotic Membrane (Prokera, Fresh)³
• ☐ 5. Amniotic Membrane Drops (CAM360, etc.)³
• ☐ 6. Systemic Immunomodulators (Acthar Gel, Methotrexate, Mycophenolate)^4,5,6
• ☐ 7. Xiidra (Lifitegrast)⁷
• ☐ 8. Cyclosporine (Restasis, Cequa, Vevye)⁸
• ☐ 9. Intense Pulsed Light (IPL)⁹
• ☐ 10. Radiofrequency (RF)⁹
• ☐ 11. Low‑Level Light Therapy (LLLT)¹⁰
• ☐ 12. Stem Cell Drops (experimental)¹¹

STEROIDAL ANTI‑INFLAMMATORY OPTIONS
(Ranked strongest → milder)

• ☐ 1. Difluprednate 0.05% (Durezol)¹²
• ☐ 2. Prednisolone Acetate 1%¹²
• ☐ 3. Dexamethasone 0.1% Solution¹²
• ☐ 4. Dexamethasone 0.1% Ointment (NPD 1%)¹²
• ☐ 5. Intracanalicular Dexamethasone Insert (Dextenza)¹³
• ☐ 6. Subconjunctival Steroid Injection¹⁴
• ☐ 7. Oral Corticosteroids¹⁵
• ☐ 8. Loteprednol Etabonate 0.5%¹⁶

REFERENCES (PubMed‑Oriented Summary)

1. PRP eye drops: randomized and prospective studies show significant improvement in symptoms and staining in moderate–severe dry eye.
2. PRP vs Autologous Serum: systematic reviews/meta‑analyses show both effective; PRP often contains higher growth factor levels.
3. Autologous Serum Tears: multiple RCTs show improved tear function and ocular surface staining in severe dry eye and Sjögren’s.
4. Cord Blood Serum: clinical studies show enhanced epithelial healing and symptom relief, especially in severe/pediatric disease.
5. Amniotic Membrane: strong evidence for epithelial healing, anti‑inflammatory effects, and pain reduction in persistent epithelial defects.
6. Amniotic‑derived drops: early clinical data show symptomatic and epithelial improvements.
7. Lifitegrast: RCTs show improvement in symptoms and signs via LFA‑1/ICAM‑1 blockade.
8. Cyclosporine: numerous RCTs demonstrate improved tear production and reduced T‑cell–mediated inflammation.
9. IPL/RF: prospective studies show reduced meibomian gland inflammation and improved gland function.
10. LLLT: early clinical data show reduction in inflammatory mediators and improved gland function.
11. MSC therapies: preclinical and early clinical studies show immunomodulatory and regenerative effects.
12. Exosomes: experimental and early clinical work shows epithelial and nerve‑regenerative potential.
13. Topical steroid potency: difluprednate > pred acetate > dexamethasone > loteprednol based on comparative trials.
14. Dextenza: RCTs show effective postoperative inflammation control.
15. Subconjunctival steroids: strong evidence for high local anti‑inflammatory effect.
16. Oral steroids: systemic anti‑inflammatory effect with robust evidence across autoimmune ocular disease.
17. Loteprednol: ester‑based steroid with lower IOP‑raising risk and strong anti‑inflammatory efficacy.